Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Anemia » Anemia, Hemolytic
Description
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES). MeSH
Hierarchy View
Subtype Terms (5)
Anemia, Hemolytic, Autoimmune
44 drugs (27 approved, 17 experimental)
Anemia, Hemolytic, Congenital
3 approved drugs
Favism
1 approved drug
Hemoglobinuria, Paroxysmal
49 drugs (26 approved, 23 experimental)
Hemolytic-Uremic Syndrome
5 drugs (4 approved, 1 experimental)
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (2)
Phase 2 Indicated Drugs (4)
Phase 1 Indicated Drugs (3)
Other Experimental Indicated Drugs (1)
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (29)
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
